“Because it’s a living organism, we can engineer our tularemia vaccine to produce 'pieces' of the SARS CoV-2 virus, which will allow the host to recognize it and make antibodies against it," said Karl Klose, a UTSA microbiology professor and director of the South Texas Center for Emerging Infectious Diseases. "We hope that these antibodies will protect people against COVID-19, in addition to tularemia."San Antonio Partnership for Precision Therapeutics issued a call for COVID-19 funding proposals shortly after the coronavirus swept into Texas. Within a week, it received 17 and ultimately selected the UTSA consortium for the grant.
Support Local Journalism.
Join the San Antonio Current Press Club
Local journalism is information. Information is power. And we believe everyone deserves access to accurate independent coverage of their community and state. Our readers helped us continue this coverage in 2020, and we are so grateful for the support.
Help us keep this coverage going in 2021. Whether it's a one-time acknowledgement of this article or an ongoing membership pledge, your support goes to local-based reporting from our small but mighty team.
Join the San Antonio Press Club for as little as $5 a month.